We are well into 2025 so saying Happy New Year is not appropriate anymore. I think now people are asking others how they are doing with their resolutions. I have just one goal this year and that is to learn something new. I’ll let you know how I do. Send me your resolutions in the comment section.

I am excited for you to listen to my conversation with Dr. Brian Fiske, Chief Scientist for the MJFF. I like to kick off the new year/new season with a medication update. This year we are going to get an update on the research landscape and what it means compared to previous years. There are therapies in various stages of clinical testing using several different therapeutic approaches.  It is exciting to learn about what to expect in the future and how we all can contribute to move things forward faster.

Let’s learn from Dr. Fiske what we now know about the biology of Parkinson’s, genetics and the environment’s contribution, the advances in testing for a Parkinson’s diagnosis, and where we stand in slowing the progression of the disease.

This podcast is sponsored by  CND Life Sciences, home of the Syn-One Test ® - the first commercially available skin-based test to help clinicians diagnose Parkinson’s and related disorders. CND Life Sciences supports the care of patients facing the potential diagnosis of a neurodegenerative disease. CND’s Syn-One Test® helps clinicians to diagnose suspected synucleinopathies using skin biopsies to detect, visualize, and quantify phosphorylated alpha-synuclein located in nerves in the skin. The Syn-One Test is performed in CND’s CLIA-certified and CAP-accredited laboratory located in Scottsdale, AZ.  

https://www.michaeljfox.org/state-field

https://www.michaeljfox.org/ppmi

https://www.michaeljfox.org/trial-finder

https://cndlifesciences.com/

https://cndlifesciences.com/syn-one-test/